A study of carfilzomib, lenalidomide and dexamethasone (KRd) plus high-dose therapy with melphalan-200 and autologous stem cell transplantation, followed by consolidation with KRd, and maintenance with lenalidomide and dexamethasone in patients with high risk smoldering multiple myeloma (SMM) under 65 years
- Registry ID
- EUCTR2014-002948-40
- Source registry
- EUCTR
- Status
- Ongoing
- Phase
- PHASE2
- Sponsor
- Fundación PETHEMA
- Start date
- 2015-03-03
- Last update
- 2026-08-16
Conditions
- Smoldering multiple myeloma
Summary
To evaluate the rate of patients achieving and maintaining immunophenotypic response (Flow-CR) (complete response with minimal residual disease negative by multiparametric flow cytometry) at day +100 after high-dose therapy and autologous stem cell transplantation (HDT-ASCT).
Locations
View on source registry